摘要
目的探讨甲氨蝶呤(methotrexate,MTX)单次注射治疗异位妊娠的结局及相关影响因素。方法回顾性分析2019年1月至2022年12月在复旦大学附属妇产科医院住院的416例异位妊娠患者,均行MTX单次注射,用药当天记为第1天,在用药第4天和第7天复查血β-人绒毛膜促性腺激素(β-human chorionic gonadotrophin,β-hCG)。与第4天相比,第7天血β-人绒毛膜促性腺激素下降<15%为治疗失败,纳入失败组;第7天血β-hCG下降>15%,为初始治疗有效,继续随访直至β-hCG下降至正常水平,纳入成功组。收集两组患者基线信息和治疗结局,并分析与治疗结局相关的影响因素。结果失败组纳入70例,成功组纳入346例。失败组中用药前β-hCG上升人数比例显著高于成功组(55.2%vs.35.8%,P=0.007),用药前β-hCG下降人数比例显著低于成功组(43.1%vs.63.6%,P=0.007)。失败组单核细胞计数显著低于成功组[(0.43±0.13)×10^(9)/L vs.(0.47±0.17)×10^(9)/L,t=-2.001,P=0.047)]。两组用药前β-hCG、β-hCG变化速度、白蛋白、血肌酐、白细胞计数、中性粒细胞计数、血小板平均体积、中性粒细胞-淋巴细胞比值、血小板-淋巴细胞比值、淋巴细胞-单核细胞比值的差异均无统计学意义。Logistic回归分析表明治疗结局与用药前β-hCG变化方式和单核细胞计数有关,用药前β-hCG下降(OR=2.313,95%CI:1.222~4.379,P=0.010)和单核细胞计数≥0.6×10^(9)/L(OR=4.018,95%CI:1.207~13.378,P=0.023)对治疗结局有显著影响。结论用药前β-hCG下降和单核细胞计数≥0.6×10^(9)/L是MTX单次注射成功治疗异位妊娠的独立影响因素。
Objective To analyze factors affecting outcomes of single-dose methotrexate(MTX)treatment in patients with ectopic pregnancy.Methods The data of 416 patients with ectopic pregnancy treated by single-dose MTX injection in Obstetrics and Gynecology Hospital,Fudan University from Jan 2019 to Dec 2022 were retrospectively analyzed.MTX was administered on day 1,and the serumβ-human chorionic gonadotrophin(β-hCG)levels were measured on posttreatment day 4 and day 7.If serumβ-hCG level decreased less than 15%,it was considered as treatment failure,thus the patient was included in the failure group.If serumβ-hCG level decreased more than 15%,it was considered as effective initial treatment andβ-hCG levels were measured weekly until back to nonpregnant level,thus the patient was included in the success group.Clinical data and treatment outcomes were collected and outcomes-related risk factors were analyzed.Results There were 70 patients in failure group and 346 patients in success group.The proportion of patients with increasedβ-humanchorionic gonadotrophin(β-hCG)level before MTX treatment in failure group was significantly higher than that of patients in success group(55.2%vs.35.8%,P=0.007)and the proportion of patients with decreasedβ-hCG level before MTX treatment in failure group was significantly lower than that of patients in success group(43.1%vs.63.6%,P=0.007).Monocyte counts in failure group was significantly lower than that in success group[(0.43±0.13)×10^(9)/L vs.(0.47±0.17)×10^(9)/L,t=-2.001,P=0.047)].The differences of basalβ-hCG level,change speed ofβ-hCG level,serum albumin,serum creatinine,white blood cell,neutrocyte,mean platelet volume,neutrocyte-lymphocyte ratio,platelet-lymphocyte ratio and lymphocyte-monocyte ratio between the two groups were not significant.Logistic regression analysis suggested the changing patterns of serumβ-hCG level and monocyte counts were associated with treatment outcomes.Decreasedβ-hCG level(OR=2.313,95%CI:1.222-4.379,P=0.010)and monocyte counts≥0.6×10^(9)/
作者
林晓龙
姜文清
邹世恩
LIN Xiao-long;JIANG Wen-qing;ZOU Shi-en(Department of Gynecology,Obstetrics and Gynecology Hospital,Fudan University,Shanghai 200011,China)
出处
《复旦学报（医学版）》
CAS
CSCD
北大核心
2024年第3期378-384,共7页
Fudan University Journal of Medical Sciences
